Pharming Group NV

PHARNYSE EURONEXT - EURONEXT AMSTERDAM

Health CareBiotechnology

$12.99

-0.670000 (-4.90%)

As of 05/29/26 EDT · USD

Compare

52-Week Low: $9.54Current: $12.9952-Week High: $21.34

Key Statistics

Open

$13.44

Day High

$13.44

Day Low

$12.99

Prev. Close

$13.66

Volume

21.31K

Avg. Volume

—

Market Cap

$917.42M

P/E (TTM)

—

Forward P/E

—

P/B Ratio

—

52W High

$21.34

52W Low

$9.54

50D MA

$15.46

200D MA

$15.71

Dividend Yield

—

Beta

—

Performance

+1.4%

-20.6%

-23.8%

YTD

-24.2%

+22.5%

About

Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy 2V, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to a deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA). The inability to break down glycogen within the lysosomes of cells leads to progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and the nervous system.

www.pharming.com/